Prognostic Scoring Systems in Primary Biliary Cholangitis: An Update

Clin Liver Dis. 2022 Nov;26(4):629-642. doi: 10.1016/j.cld.2022.06.005. Epub 2022 Sep 14.

Abstract

Primary biliary cholangitis (PBC) is a complex, chronic disease with a heterogeneous presentation, disease progression, and response to therapy. Several prognostic models based on disease stage and/or treatment response enhance risk stratification and therapeutic management. Recent work on disease modeling proposed early prediction of outcomes at PBC onset, yet this has not been implemented in clinical practice. Although early stratification of patients based on their individual risk of developing end-stage liver disease may prove cost-effective and actually become matter of medical deontology to timely offer the best therapeutic option, given the forthcoming availability of novel, disease-modifying drugs. This review outlines established and novel prognostic systems in PBC and provides some perspectives on the potential role of omics-derived biomarkers in developing reliable risk prediction models and promoting the implementation of personalized medicine in PBC.

Keywords: Autoimmune liver disease; Prediction; Primary biliary cholangitis; Prognostic models; Risk-stratification.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Cholangitis* / therapy
  • End Stage Liver Disease*
  • Humans
  • Liver Cirrhosis, Biliary* / diagnosis
  • Liver Cirrhosis, Biliary* / drug therapy
  • Prognosis

Substances

  • Biomarkers